Aptamer Group plc announced the appointment of Rob Quinn as Chief Financial Officer, effective from 1 March 2023. Rob brings a wealth of both scientific and financial experience with particular expertise in publicly listed biotechnology and pharmaceutical companies. From 2019-2021 he was CFO of Silence Therapeutics, where he oversaw the growth of the company from a $50 million to $500 million market capitalisation.

Rob was subsequently CFO at BenevolentAI until January 2022, where he played a key role in the company's European reverse merger into a SPAC listed on Euronext Amsterdam. Most recently, Rob was CFO at Pharnext, a biotech company listed on Euronext Paris. Rob has a BSc in Cell and Molecular Biology from University College Dublin and a PhD in Biochemistry from the University of Manchester.

He is anAssociate of The Institute of Chartered Accountants in England and Wales.